Eli Lilly and Company (NYSE:LLY) Shares Acquired by Montis Financial LLC

Montis Financial LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 9.4% in the fourth quarter, HoldingsChannel reports. The fund owned 464 shares of the company’s stock after acquiring an additional 40 shares during the quarter. Montis Financial LLC’s holdings in Eli Lilly and Company were worth $271,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Lipe & Dalton acquired a new position in Eli Lilly and Company during the 4th quarter worth about $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter worth $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $35,000. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $36,000. Finally, Family CFO Inc purchased a new stake in Eli Lilly and Company in the third quarter valued at $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 2.8 %

NYSE:LLY traded down $20.94 during mid-day trading on Friday, reaching $734.97. The stock had a trading volume of 4,535,213 shares, compared to its average volume of 3,087,178. The stock has a market cap of $698.52 billion, a P/E ratio of 108.24, a PEG ratio of 1.57 and a beta of 0.37. The business’s 50 day moving average is $761.75 and its 200 day moving average is $670.56. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.62 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.49 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on LLY shares. Bank of America upped their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup lifted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Finally, TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.